Answers are grounded in this paper and cite their sources.
Retrospective study shows reduced hospitalization in patients treated with REGEN-COV, indicating improved outcomes in COVID-19.
Background: Casirivimab–imdevimab (REGEN-COV) is a neutralizing antibody cocktail that has been shown to prevent the progression of COVID-19 and serious adverse outcomes in patients with COVID-19 disease. During the period preceding the emergence of the Omicron variant, REGEN-COV demonstrated clinical activity against several circulating SARS-CoV-2 variants. The delta variant was dominant worldwide during much of the study period. Aim: This retrospective observational study aimed to show the single centre’s results in treating patients with REGEN-COV. Methods: This study included adult patients who received REGEN-COV at our COVID-19 centre from 01 June 2021 to 31 January 2022 (REGEN-COV group) and a comparison group that included patients who did not meet the eligibility criteria for REGEN-COV (non-REGEN-COV group). The primary end-point was the need for hospitalization. The secondary end-point was all-cause mortality. Intensive care unit admission was also evaluated. Results: This study included 206 patients, of whom 69 received REGEN-COV, and 137 comprised the non-REGEN-COV group. During follow-up, 128 patients (62%) required hospitalization, including 11 (15.9%) in the REGEN-COV group and 117 (85.4%) in the non-REGEN-COV group (p < 0.001). Mortality occurred in 2 patients (2.9%) treated with REGEN-COV compared with 30 patients (21.9%) in the non-REGEN-COV group. In the propensity score-matched analysis, the average marginal absolute risk difference for mortality between the groups was −4.0% (95% CI −9.8 to 1.8), p = 0.178; however, Kaplan–Meier survival analysis demonstrated a significant difference in survival between groups (log-rank p < 0.001). Conclusions: Our study showed that in high-risk patients, with specific variants of SARS-CoV-2, the use of REGEN-COV was associated with a lower risk of hospitalization, and it was associated with better disease outcomes. One of the limitations of this study was the variant-specific effectiveness of REGEN-COV, which may limit generalizability.
No takes yet. Share an insight, caveat, or question.
Popovic et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: